Questioning the value of 99mTc-HYNIC-annexin V based response monitoring after docetaxel treatment in a mouse model for hereditary breast cancer

Applied Radiation and Isotopes

Volumn 69, Issue 4, 2011, Pages 656-662

  Beekman, Chantal A C ^a   Buckle, Tessa ^a   van Leeuwen, Anne C ^a   Valdés Olmos, Renato A ^a   Verheij, Marcel ^a   Rottenberg, Sven ^a   Van Leeuwen, Fijs W B ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Annexin V; Apoptosis imaging; Response prediction; SPECT CT; Tumor models

Indexed keywords

ANNEXINS; APOPTOSIS IMAGING; RESPONSE PREDICTION; SPECT/CT; TUMOR MODELS;

ANIMALS; ANTIBIOTICS; CELL DEATH; DISEASES; FORECASTING;

TUMORS;

DOCETAXEL; RADIOPHARMACEUTICAL AGENT; TECHNETIUM HYDRAZINONICOTINAMIDE ANNEXIN V TC 99M; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CHEMOSENSITIVITY; COMPUTER ASSISTED TOMOGRAPHY; CONE BEAM COMPUTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TUMOR LEVEL; FAMILIAL CANCER; FEMALE; GENETIC VARIABILITY; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MOUSE; NONHUMAN; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOISOTOPE DIAGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; ANNEXIN A5; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; MICE; ORGANOTECHNETIUM COMPOUNDS; TAXOIDS;

EID: 79551690068     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2010.12.012     Document Type: Article

References (52)

1. Bardelmeijer H.A., Roelofs A.B., Hillebrand M.J., Beijnen J.H., Schellens J.H., van Tellingen O. Metabolism of docetaxel in mice. Cancer Chemother. Pharmacol. 2005, 56(3):299-306.
2. Bardelmeijer H.A., Oomen I.A., Hillebrand M.J., Beijnen J.H., Schellens J.H., van Tellingen O. Metabolism of paclitaxel in mice. Anticancer Drugs 2003, 14(3):203-209.
3. Belhocine T., Steinmetz N., Hustinx R., Bartsch P., Jerusalem G., Seidel L., Rigo P., Green A. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res. 2002, 8(9):2766-2774.
4. Belhocine T., Steinmetz N., Green A., Rigo P. In vivo imaging of chemotherapy-induced apoptosis in human cancers. Ann. NY Acad. Sci. 2003, 1010:525-529.
5. Blankenberg F.G., Katsikis P.D., Tait J.F., Davis R.E., Naumovski L., Ohtsuki K., Kopiwoda S., Abrams M.J., Darkes M., Robbins R.C., Maecker H.T., Strauss H.W. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc. Natl. Acad. Sci 1998, 95:6349-6354.
6. Blankenberg F. To scan or not to scan, it is a question of timing: technetium-99m-annexin v radionuclide imaging assessment of treatment efficacy after one course of chemotherapy. Clin. Cancer Res. 2002, 8:2757-2758.
7. Blankenberg F.G., Kalinyak J., Liu L., Koike M., Cheng D., Goris M.L., Green A., Vanderheyden J.L., Tong D.C., Yenari M.A. 99mTc-HYNIC-annexin V SPECT imaging of acute stroke and its response to neuroprotective therapy with anti-Fas ligand antibody. Eur. J. Nucl. Med. Mol. Imag. 2006, 33:566-574.
8. Boersma H.H., Kietselaer B.L.J.H., Stolk L.M.L., Bennaghmuoch A., Hofstra L., Narula J., Heidendal G.A.K., Reutelingsperger C.P.M. Past, present, and future of annexin A5: from protein discovery to clinical applications. J. Nucl. Med. 2005, 46:2035-2050.
9. Bullok K.E., Maxwell D., Kesarwala A.H., Gammon S., Prior J.L., Snow M., Stanley S., Piwnica-Worms D. Biochemical and in vivo characterization of a small, membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. Biochemistry 2007, 46(13):4055-4065.
10. Damianovich M., Ziv I., Heyman S.N., Rosen S., Shina A., Kidron D., Aloya T., Grimberg H., Levin G., Reshef A., Bentolila A., Cohen A., Shirvan A. ApoSense: a novel technology for functional molecular imaging of cell death in models of acute renal tubular necrosis. Eur. J. Nucl. Med. Mol. Imag. 2006, 33(3):281-291.
11. Eom Y.W., Kim M.A., Park S.S., Goo M.J., Kwon H.J., Sohn S., Kim W.H., Yoon G., Choi K.S. Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 2005, 24(30):4765-4777.
12. Erba P.A., Manfredi C., Lazzeri E., Minichilli F., Pauwels E.K.J., Sbrana A., Strauss H.W., Mariani G. Time course of paclitaxel-induced apoptosis in an experimental model of virus-induced breast cancer. J. Nucl. Med. 2010, 51(5):775-781.
13. Evan G.I., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411(6835):342-348.
14. Fabbri F., Amadori D., Carloni S., Brigliadori G., Tesei A., Ulivi P., Rosetti M., Vannini I., Arienti C., Zoli W., Silvestrini R. Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells. J. Cell. Physiol. 2008, 217(2):494-501.
15. Futter C.E., White I.J. Annexins and endocytosis. Traffic 2007, 8:951-958.
16. Garanger E., Hilderbrand A., Blois J.T., Sosnovik D.E., Weissleder R., Josephson L. A DNA-binding Gd chelate for the detection of cell death by MRI. Chem. Commun. 2009, 29:4444-4446.
17. Grosse J., Grimm D., Westphal K., Ulbrich C., Moosbauer J., Pohl F., Koelbl O., Infanger M., Eilles C., Schoenberger J. Radiolabeled annexin V for imaging apoptosis in radiated human follicular thyroid carcinomas-is an individualized protocol necessary?. Nucl. Med. Biol. 2009, 36(1):89-98.
18. Guo M., Zhao Y., Tian R., Li L., Guo L., Xu F., Liu Y., He Y., Bai S., Wang J. In vivo99mTc-HYNIC-annexin V imaging of early tumor apoptosis in mice after single dose irradiation. J. Exp. Clin. Cancer Res. 2009, 28:136.
19. Hammill A.K., Uhr J.W., Scheuermann R.H. Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. Exp. Cell Res. 1999, 251:16-21.
20. Jones S.E., Erban J., Overmoyer B., Budd G.T., Hutchins L., Lower E., Laufman L., Sundaram S., Urba W.J., Pritchard K.I., Mennel R., Richards D., Olsen S., Meyers M.L., Ravdin P.M. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol. 2005, 23(24):5542-5551.
21. Kartachova M.S., Valdes Olmos R.A., Haas R.L.M., Hoebers F.J.P., van Herk M., Verheij M. 99mTc-HYNIC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome. Nucl. Med. Commun. 2008, 29:39-44.
22. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972, 26(4):239-257.
23. Kroemer G., Galluzzi L., Vandenabeele P., Abrams J., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., El-Deiry W.S., Golstein P., Green D.R., Hengartner M., Knight R.A., Kumar S., Lipton S.A., Malorni W., Nuñez G., Peter M.E., Tschopp J., Yuan J., Piacentini M., Zhivotovsky B., Melino G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009, 16(1):3-11.
24. Kuge Y., Sato M., Zhao S., Takei T., Nakada K., Seki K., Strauss H.W., Blankenberg F.G., Tait J.F., Tamaki N. Feasibility of 99mTc-Annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model. J. Nucl. Med. 2004, 45(2):309-312.
25. Lampl Y., Lorberboym M., Blankenberg F.G., Sadeh M., Gilad R. Annexin V SPECT imaging of phosphatidylserine expression in patients with dementia. Neurology 2006, 66:1253-1254.
26. Liu X., Holstege H., van der Gulden H., Treur-Mulder M., Zevenhoven J., Velds A., Kerkhoven R.M., van Vliet M.H., Wessels L.F., Peterse J.L., Berns A., Jonkers J. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl. Acad. Sci. 2007, 104(29):12111-12116.
27. Lock R.B., Stribinskiene L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res. 1996, 56:4006-4012.
28. Mandl S.J., Mari C., Edinger M., Negrin R.S., Tait J.F., Contag C.H., Blankenberg F.G. Multi-modality imaging identifies key times for Annexin V imaging as an early predictor of therapeutic outcome. Mol. Imag. 2004, 3(1):1-8.
29. Meier P., Finch A., Evan G. Apoptosis in development. Nature 2000, 407:796-801.
30. Mochizuki T., Kuge Y., Zhao S., Tsukamoto E., Hosokawa M., Strauss H.W., Blankenberg F.G., Tait J.F., Tamaki N. Detection of apoptotic tumor response in vivo after a single dose of chemotherapy with 99mTc-Annexin V. J. Nucl. Med. 2003, 44(1):92-97.
31. Mukherjee A., Kothari K., Toth G., Szemenyei E., Dhar Sarma H., Kornyei J., Venkatesh M. 99mTc-labeled annexin V fragments: a potential SPECT radiopharmaceutical for imaging death. Nucl. Med. Biol. 2006, 33:635-643.
32. Narula J., Strauss H.W. Invited commentary: P.S.*I love you: implications of phosphatidyl serine (PS) reversal in acute ischemic syndromes. J. Nucl. Med. 2003, 44:397-3399.
33. Nicotera P., Melino G. Regulation of the apoptosis-necrosis switch. Oncogene 2004, 23:2757-2765.
34. Nieves-Neira W., Pommer Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI anticancer drug screen: Multifactorial relationships with topoisomerase 1, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. Int. J. Cancer 1999, 82:396-404.
35. Ohnishi S., Vanderheyden J.L., Tanaka E., Patel B., De Grand A.M., Laurence R.G., Yamashitab K., Frangioni J.V. Intraoperative detection of cell injury and cell death with an 800nm near-infrared fluorescent annexin V derivative. Am. J. Transplant. 2006, 6(10):2321-2331.
36. Paijic M., Iyer J.K., Kersbergen A., van der Burg E., Nygren A.O., Jonkers J., Borst P., Rottenberg S. Moderate increase in Mdr1a/b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res. 2009, 69(16):6396-6404.
37. Podichetty A.K., Wagner S., Schröer S., Faust A., Schäfers M., Schober O., Kopka K., Haufe G. Fluorinated isatin derivatives. Part 2. New N-substituted 5-pyrrolidinylsulfonyl isatins as potential tools for molecular imaging of caspases in apoptosis. J. Med. Chem. 2009, 52(11):3484-3495.
38. Roninson I.B., Broude E.V., Chang B.D. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist. Updat. 2001, 4(5):303-313.
39. Rottenberg S., Nygren A.O.H., Pajic M., van Leeuwen F.W.B., van der Heijden I., van de Wetering K., Liu X., de Visser K.E., Gilhuijs K.G., van Tellingen O., Schouten J.P., Jonkers J., Borst P. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl. Acad. Sci. 2007, 104(29):12117-12122.
40. Rottey S., Slegers G., van Belle S., Goethals I., Van de Wiele C. Sequential 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy. J. Nucl. Med. 2006, 47:1813-1818.
41. Smith C., Gibson F., Tait J.F. Transmembrane voltage regulates binding of annexin V and lactadherin to cells with exposed phosphatidylserine. BMC Biochemistry 2009, 10(5):1-8.
42. Stadelmann C., Lassmann H. Detection of apoptosis in tissue sections. Cell Tissue Res. 2000, 301(1):19-31.
43. Strauss H.W., Narula J., Blankenberg F.G. Radioimaging to identify myocardial cell death and probably injury. Lancet 2000, 356:180-181.
44. Tang H.L., Yuen K.L., Tang H.M., Fung M.C. Reversibility of apoptosis in cancer cells. Br. J. Cancer 2009, 100:118-122.
45. Takei T., Kuge Y., Zhao S., Sato M., Strauss H.W., Blankenberg F.G., Tait J.F., Tamaki N. Time course of apoptotic tumor response after a single dose of chemotherapy: comparison with 99mTc-Annexin V uptake and histologic findings in an experimental model. J. Nucl. Med. 2004, 45(12):2083-2087.
46. Thimister P.W., Hofstr L., Liem I.H., Boersma H.H., Kemerink G., Reutelingsperger C.P., Heidendal G.A.K. In vivo detection of cell death in the area at risk in acute myocardial infarction. J. Nucl. Med. 2003, 44:391-396.
47. Vakifahmetoglu H., Olsson M., Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ 2008, 15(7):1153-1162.
48. Van de Wiele C., Lahorte C., Vermeersch H., Loose D., Mervillie K., Steinmetz N.D., Vanderheyden J.-L., Cuvelier C.A., Slegers G., Dierck R.A. Quantitative tumor apoptosis imaging using Technetium-99m-HYNIC Annexin V single photon emission computed tomography. J. Clin. Oncol. 2003, 21(18):3483-3487.
49. van Leeuwen F.W.B., Buckle T., Kersbergen A., Rottenberg S., Gilhuijs K.G. Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity. Eur. J. Nucl. Med. Mol. Imag. 2009, 36(3):406-412.
50. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Meth. 1995, 184(1):39-51.
51. Verweij J., Clavel M., Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann. Oncol. 1994, 5(6):495-505.
52. Yang D.J., Azhdarinia A., Wu P., Yu D.-F., Tansey W., Kohanim S., Kalimi E., Kim E., Podoloff D.A. In vivo and in vitro measurement of apoptosis in breast cancer cells using 99mTc-EC-Annexin V. Cancer Biother. Radiopharm. 2001, 16(1):73-83.